Home/Pipeline/CEL-301

CEL-301

Undisclosed Oncology

PreclinicalActive

Key Facts

Indication
Undisclosed Oncology
Phase
Preclinical
Status
Active
Company

About Celon Pharma

Celon Pharma's mission is to develop and provide innovative therapies for diseases with significant unmet medical needs, primarily in oncology and CNS, while maintaining financial stability through its generic drug operations. Its key achievement is building a fully integrated, GMP/GLP-compliant biopharma platform in Poland, supporting a pipeline of 11 proprietary drug candidates. The company's strategy is defined by this self-funded, end-to-end model, which reduces external dependencies and aims to capture full value from its R&D successes. This approach has established Celon as a unique and strategically important player in the European biopharmaceutical landscape.

View full company profile

Other Undisclosed Oncology Drugs

DrugCompanyPhase
TAK-186Thermo Fisher ScientificPhase 1
ODM-209Orion CorporationPhase 1
ARV-393ArvinasPhase 1
ARV-6723ArvinasPhase 1
ARV-806ArvinasPhase 1
ARV-027ArvinasPhase 1